Merck Q1 2026 sales rise 5% to $16.3B; non-GAAP loss of $1.28 per share after Cidara charge; guidance raised

Merck reported first-quarter 2026 sales of $16.3 billion, up 5% (3% excluding currency), with Keytruda and Keytruda Qlex at $8.0 billion, up 12%. The company posted a non-GAAP loss of $1.28 per share and a GAAP loss of $1.72 per share, both including a $3.62-per-share charge for Cidara. Merck narrowed and raised its 2026 sales outlook to $65.8 billion to $67.0 billion and its non-GAAP EPS outlook to $5.04 to $5.16, excluding the expected Terns charge.

• Sales $16.3B, up 5% (up 3% ex-FX)
• Keytruda and Keytruda Qlex $8.0B, up 12%; Winrevair $525M, up 88%; Gardasil $1,069M, down 19%
• Non-GAAP EPS loss of $1.28; GAAP loss of $1.72, including $3.62 per share Cidara charge
• 2026 guidance: sales $65.8B to $67.0B; non-GAAP EPS $5.04 to $5.16 (excludes Terns)
• Terns charge expected at about $5.8B, or $2.35 per share

SEC filing 8-K · accession 0001104659-26-052081 · sec.gov ↗